ROZEREM Drug Patent Profile

When do Rozerem patents expire, and what generic alternatives are available?

Rozerem is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in ROZEREM is ramelteon. There are three drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ramelteon profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rozerem

A generic version of ROZEREM was approved as ramelteon by DR REDDYS LABS SA on July 26^th, 2013.

Summary for ROZEREM

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for ROZEREM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ROZEREM	Tablets	ramelteon	8 mg	021782	2	2009-07-22

US Patents and Regulatory Information for ROZEREM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	ROZEREM	ramelteon	TABLET;ORAL	021782-001	Jul 22, 2005	AB	RX	Yes	Yes

International Patents for ROZEREM

See the table below for patents covering ROZEREM around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	885210
Austria	219071
Poland	188093
China	100441574
European Patent Office	2305219
Japan	2004300160	MEDICAL PREPARATION CONTAINING COPOLYBIDONE

ROZEREM (Ramelteon) Investment and Fundamentals Analysis

Last updated: February 20, 2026

What is the current market outlook for ROZEREM (Ramelteon)?

ROZEREM (ramelteon) is a sedative-hypnotic agent approved for the treatment of insomnia characterized by difficulty with sleep onset. Since its US approval in 2005 by the FDA, it has maintained a niche position within sleep disorder therapeutics. The drug targets melatonin receptor subtypes MT1 and MT2, influencing circadian sleep-wake cycles. Its market penetration remains limited relative to other sleep aids, such as zolpidem and suvorexant, due to regulatory and patent considerations.

Global sales peaked at approximately $104 million in 2020, with modest declines observed in subsequent years, partly due to generic competition and market saturation. Industry forecasts project a compound annual growth rate (CAGR) of roughly 2% for melatonin receptor agents over the next five years, reaching an estimated $120 million by 2028.

How does ROZEREM perform financially?

ROZEREM’s revenue stream is primarily derived from the U.S. market, as regulatory approvals outside North America are limited or pending. The drug is marketed by Takeda Pharmaceuticals, which acquired the rights from its original developer, Merck.

Metric	2020	2021	2022 (est.)	2023 (projected)
Total global sales	$104 M	$95 M	$90 M	$88 M
U.S. market share	75%	70%	68%	65%
Number of prescriptions (U.S.)	4 million	3.8 million	3.6 million	3.5 million

Competition comes from other sleep aids, including benzodiazepines, non-benzodiazepine hypnotics, and orexin receptor antagonists, which tend to have broader indications or more aggressive marketing.

What are the patent and regulatory landscapes?

Ramelteon’s original composition patent expired in 2015, opening the market to generics. Takeda maintains exclusivity through a formulation patent, which expired in 2020. This loss of patent protection caused a significant decline in sales volume and revenue, as generic formulations entered the market.

Labeling restrictions limit the prescribing of ramelteon for use outside sleep-onset insomnia, constraining sales potential. Confirmed regulatory pathways exist in Canada and several European countries, but market entry remains slow due to regulatory heterogeneity.

What are the key development and pipeline considerations?

There are no significant new clinical developments associated with ramelteon. However, research on melatonin receptor agonists continues to evolve, with newer compounds under investigation for broader indications, such as jet lag disorder, shift work disorder, and depression-related sleep disturbance.

Investments into combination therapies, extended-release formulations, or novel delivery methods could restore market interest. No current pipeline drugs directly suggest reformulations or derivatives of ramelteon are under active development.

What are the investment risks?

• Patent expiry and resultant generics threaten revenue.
• Market share constraints due to safety profile concerns, including reports of dizziness and fatigue.
• Competition from newer agents with broader approval and more convenient dosing.
• Regulatory limitations in multiple jurisdictions delay expansion.

What is the strategic outlook?

Investors and R&D firms should consider the following:

• The drug’s limited growth prospects due to patent expiration and market saturation.
• Opportunities in niche markets and off-label uses, with minimal regulatory barriers.
• Potential licensing or development of combination regimens to expand indications.
• The broader sleep disorder market, which remains fragmented but steadily growing at modest rates.

Key Takeaways

• ROZEREM remains a specialized sleep treatment with limited growth.
• Patent expiry in 2015 led to generic penetration, diminishing sales.
• Market expansion opportunities are constrained by regulatory and safety limitations.
• The global sleep aid market is projected to grow slowly, favoring established agents.
• Future value hinges on pipeline innovation, new indications, or licensing deals.

FAQs

1. How significant is the patent expiration for ROZEREM?
Patent expiration in 2015 led to generic competition, causing sales decline and reducing profitability margins for Takeda.

2. Are there opportunities for new formulations?
Potential exists in extended-release formulations or combination therapies, but no active pipeline projects target these strategies presently.

3. What are the main competitors?
Zolpidem, eszopiclone, suvorexant, and lemborexant comprise the primary competitors, often with broader approvals and market share.

4. Can ROZEREM expand internationally?
Yes, but regulatory approval varies and is often slow; market penetration outside the U.S. remains limited.

5. What trends could revive interest in ramelteon?
Research into sleep disorder biomarkers, personalized treatment, or combination to improve safety and efficacy could provide avenues for revitalization.

---

References

1. U.S. Food and Drug Administration (2005). Approval of ROZEREM.
2. IQVIA (2022). Global sleep aid market report.
3. Takeda Pharmaceuticals (2021). Annual report.
4. European Medicines Agency (2022). Ramelteon dossier.
5. MarketWatch (2022). Sleep disorder therapeutics forecast.